Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
$1.48
$1.48
$0.63
$1.51
$60.83M1.25735,654 shsN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$9.98
$0.88
$1.65
$62.85M1.23269,831 shs206,800 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.92
+1.9%
$1.90
$1.12
$4.20
$141.62M0.92279,744 shs35,177 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.55
+1.6%
$1.53
$0.82
$3.10
$122.99M-0.23601,872 shs579,693 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00%0.00%0.00%0.00%+77.20%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00%0.00%0.00%0.00%0.00%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+2.17%-3.09%+13.25%-4.08%+25.33%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+4.83%+7.04%+8.57%-42.21%+38.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.268 of 5 stars
3.31.00.00.00.00.00.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.8393 of 5 stars
3.53.00.00.01.80.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00
N/AN/AN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00
N/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50239.43% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00870.87% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/A$3.49 per shareN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/A$2.13 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M2.06$0.09 per share17.80$0.47 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.98N/A-21.03%-30.89%-11.74%N/A

Latest AVRO, IKT, PLX, and ACHL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/A
6.04
6.04
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/A
26.17
26.17
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
56.38%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
62.63%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
5.38%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
9.20%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
25041.10 million38.89 millionNot Optionable
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1344.89 million40.76 millionOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable

Recent News About These Companies

Protalix BioTherapeutics Names SVP and CFO
Protalix BioTherapeutics welcomes new finance chief
PLX: First Quarter Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achilles Therapeutics stock logo

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

AVROBIO stock logo

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.92 +0.04 (+1.86%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.54 +0.03 (+1.64%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.